Skip to Content
Merck
CN

45720

Eserine salicylate salt

≥97.0% (N)

Synonym(s):

Physostigmine salicylate salt

Sign In to View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C15H21N3O2 · C7H6O3
CAS Number:
Molecular Weight:
413.47
Beilstein:
3900576
EC Number:
MDL number:
UNSPSC Code:
12352005
PubChem Substance ID:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

Assay

≥97.0% (N)

form

powder

optical activity

[α]20/D −77±2°, c = 1% in ethanol

mp

181-183 °C

SMILES string

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1

InChI key

HZOTZTANVBDFOF-PBCQUBLHSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

F H Norris et al.
Clinical pharmacology and therapeutics, 54(6), 680-682 (1993-12-01)
We evaluated a double-blind, placebo-controlled, and double-crossover trial of oral physostigmine salicylate for a 9-month period in 13 of 25 patients with sporadic amyotrophic lateral sclerosis (ALS). A large dropout rate of 48% was secondary to eight deaths and four
S Rubnov et al.
Journal of pharmaceutical and biomedical analysis, 18(6), 939-945 (1999-01-30)
A simple stability-indicating HPLC assay has been developed for physostigmine salicylate, capable of following its degradation. A 250 x 5 mm i.d. column packed with 10 microm Bondapak C18 was used, with a mobile phase of acetonitrile - ammonium acetate
D K Lim et al.
Pharmacology, biochemistry, and behavior, 31(3), 627-631 (1988-11-01)
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in guinea pigs. Both blood and brain cholinesterase activity
C Lindén et al.
Current eye research, 16(11), 1166-1170 (1997-12-13)
To investigate if part of the progressive reduction of intraocular pressure (IOP), seen when physostigmine is applied on alternate hours, is due to a reduced aqueous flow. In a randomized, open study, one drop of physostigmine salicylate, 8 mg/ml, was
M K Johnson et al.
Toxicology and applied pharmacology, 92(1), 34-41 (1988-01-01)
Organophosphorus-induced delayed polyneuropathy (OPIDP) is thought to result from organophosphorylation of neuropathy target esterase (NTE; formerly known as neurotoxic esterase), followed by an "aging" of the phosphorylated NTE. Protection against OPIDP should thus be achieved by production of an inhibited

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service